KYMERA THERAPEUTICS INC. - COMMON STOCK

Kymera Therapeutics Strengthens Leadership Team with the Appointment of Vijay Sabesan as Senior Vice President, Technical Operations

06 Dec 2021 07:00:03 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413

30 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics to Host Virtual R&D Day on December 16, 2021

17 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

12 Nov 2021 06:00:02 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Business Update

10 Nov 2021 06:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics to Present New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting and the 63rd American Society of Hematology (ASH) Annual Meeting

04 Nov 2021 07:00:03 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming Fourth Quarter Investor Conferences

01 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents Positive Data Demonstrating Robust IRAK4 Degradation and First Proof-of-Biology with Inhibition of Cytokine Induction from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers

27 Oct 2021 06:00:01 By Nasdaq GlobeNewswire

Kymera to Hold Webcast and Conference Call Discussing Data from its KT-474 Phase 1 Trial to Be Presented at the 4th Annual Targeted Protein Degradation Summit on October 27th

20 Oct 2021 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics to Present Pharmacokinetic and Pharmacodynamic Data, including Cytokines, from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers at the 4th Annual Targeted Protein Degradation Summit

13 Oct 2021 06:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update

06 Aug 2021 06:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality

29 Jul 2021 06:00:02 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders Showing Antitumor Activity in STAT3 Mutant and Wild-Type Peripheral T-Cell Lymphoma at 13th Annual T-Cell Lymphoma Forum

12 Jul 2021 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

06 Jul 2021 15:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

30 Jun 2021 20:45:35 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Proposed Public Offering of Common Stock

28 Jun 2021 15:36:38 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism

28 Jun 2021 05:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Appoints Elaine Caughey, MBA, as Chief Business Officer

21 Jun 2021 15:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents New Preclinical Data for its IRAKIMiD Degrader KT-413 Demonstrating Strong Antitumor Activity as Both Monotherapy and in Combination in MYD88-mutant Lymphoma Models

21 Jun 2021 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics to Present New Data Demonstrating both Single-agent and Combination Regressions in MYD88-mutant Lymphoma Preclinical Models with IRAKIMiD Degrader KT-413 at 16th ICML Meeting

09 Jun 2021 07:00:02 By Nasdaq GlobeNewswire